Camilla Labrie

Camilla Labrie

Auto-generated profile, based on publicly available information

Camilla Labrie

Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Reovirus type 3 Dearing (Reo), manufactured for clinical application as pelareorep, is an attractive anticancer agent under evaluation in multiple phase 2 clinical trials for the treatment of solid tumors. It elicits its anticancer efficacy by inducing both oncolysis and intratumoral T-cell influx. Because most people have been preexposed to Reo, neutralizing antibodies (NAb) are prevalent in patients with cancer and might present a barrier to effective Reo therapy. Here, we tested serum of patients with cancer and healthy controls (n = 100) and confirmed that Reo NAbs are present in >80% of individuals. To investigate the effect of NAbs on both the oncolytic and the immunostimulatory efficacy of Reo, we established an experimental mouse model with Reo preexposure. The presence of preexposure-induced NAbs reduced Reo tumor infection and prevented Reo-mediated control of tumor growth after intratumoral Reo administration. In B cell–deficient mice, the lack of NAbs provided enhanced tumor growth control after Reo monotherapy, indicating that NAbs limit the oncolytic capacity of Reo. In immunocompetent mice, intratumoral T-cell influx was not affected by the presence of preexposure-induced NAbs and consequently, combinatorial immunotherapy strategies comprising Reo and T-cell engagers or checkpoint inhibitors remained effective in these settings, also after a clinically applied regimen of multiple intravenous pelareorep administrations. Altogether, our data indicate that NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity. Given the high prevalence of seropositivity for Reo in patients with cancer, our data strongly advocate for the application of Reo as part of T cell–based immunotherapeutic strategies.

23 February 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
CGChristianne Groeneveldt
Christianne Groeneveldt
JGJurriaan Q. van Ginkel
Jurriaan Q. van Ginkel
PKPriscilla Kinderman
Priscilla Kinderman
MSMarjolein Sluijter
Marjolein Sluijter
LGLisa Griffioen
Lisa Griffioen
NMNadine van Montfoort
Nadine van Montfoort
The absence of T cells in the tumor microenvironment of solid tumors is a major barrier to cancer immunotherapy efficacy. Oncolytic viruses, including reovirus type 3 Dearing (Reo), can recruit CD8+ T cells to the tumor and thereby enhance the efficacy of immunotherapeutic strategies that depend on high T-cell density, such as CD3-bispecific antibody (bsAb) therapy. TGF-β signaling might represent another barrier to effective Reo&CD3-bsAb therapy due to its immunoinhibitory characteristics. Here, we investigated the effect of TGF-β blockade on the antitumor efficacy of Reo&CD3-bsAb therapy in the preclinical pancreatic KPC3 and colon MC38 tumor models, where TGF-β signaling is active. TGF-β blockade impaired tumor growth in both KPC3 and MC38 tumors. Furthermore, TGF-β blockade did not affect reovirus replication in both models and significantly enhanced the Reo-induced T-cell influx in MC38 colon tumors. Reo administration decreased TGF-β signaling in MC38 tumors but instead increased TGF-β activity in KPC3 tumors, resulting in the accumulation of α-smooth muscle actin (αSMA+) fibroblasts. In KPC3 tumors, TGF-β blockade antagonized the antitumor effect of Reo&CD3-bsAb therapy, even though T-cell influx and activity were not impaired. Moreover, genetic loss of TGF-β signaling in CD8+ T cells had no effect on therapeutic responses. In contrast, TGF-β blockade significantly improved therapeutic efficacy of Reo&CD3-bsAb in mice bearing MC38 colon tumors, resulting in a 100% complete response. Further understanding of the factors that determine this intertumor dichotomy is required before TGF-β inhibition can be exploited as part of viroimmunotherapeutic combination strategies to improve their clinical benefit.Significance: Blockade of the pleiotropic molecule TGF-β can both improve and impair the efficacy of viro-immunotherapy, depending on the tumor model. While TGF-β blockade antagonized Reo&CD3-bsAb combination therapy in the KPC3 model for pancreatic cancer, it resulted in 100% complete responses in the MC38 colon model. Understanding factors underlying this contrast is required to guide therapeutic application.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S3. Kinetics of neutralizing antibodies after preexposure.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S14. Frequency of circulating phagocytic myeloid cells during Reo preexposure.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S12. Influx of immune cells after intratumoral Reo or VSV treatment of KPC3 tumors in Reo-preexposed or VSV-preexposed mice.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S9. Intratumoral T-cell influx after Reo treatment in μMT or C57BL/6J mice.